Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX112 in relapsed/refractory hematologic autoimmune disease
NL-OMON61567Phase 1Not yet recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Jul 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of zugocabtagene geleucel in autoimmune disease, sponsored by CRISPR Therapeutics. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zugocabtagene geleucel
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON61567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61567.